Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancer

RC-160 (octastatin/vapreotide) is a potent octapeptide analogue of somatostatin with growth inhibitory activity in experimental tumours in vitro and in vivo, including breast cancer. We evaluated the efficacy and tolerability of high-dose RC-160, 3 mg day(−1) on week 1 increased to 4.5 mg day(−1) fo...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: O'Byrne, K J, Dobbs, N, Propper, D J, Braybrooke, J P, Koukourakis, M I, Mitchell, K, Woodhull, J, Talbot, D C, Schally, A V, Harris, A L
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Nature Publishing Group 1999
Aiheet:
Regular Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC2362707/
https://ncbi.nlm.nih.gov/pubmed/10188884
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6690226
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia